XERS News and Press, Xeris Pharmaceuticals Inc. From 03/10/22

Xeris Biopharma (NASDAQ:XERS) entered into a senior secured term loan agreement with funds managed by Hayfin Capital Management for providing the company with up to a total of $150M of capital. "Together with the recent equity financing, which closed in January, Xeris has now added ~$80M...

Xeris Pharmaceuticals press release (NASDAQ:XERS): Q4 GAAP EPS of -$0.42 misses by $0.14. Net Product Revenue of $21.36M (+201.3% Y/Y). Cash, cash equivalents, and short-term investments at December 31, 2021, was $102.4 million compared to $133.8 million at December 31, 2020. Outlook: Ne...

Acquisition and integration of Strongbridge Biopharma completed; $50M in synergies to be realized by year-end 2022 Recorlev® approved by FDA FY ‘21 pro forma net product revenues of $79M – a 56% increase from prior year Well-capitalized with ...

$100M drawn down at close; repayment of existing term loan; near-term access to an additional $50M Provides significant operating and financial flexibility Cash flow breakeven expected by year-end 2023 Xeris Biopharma Holdings, Inc. (“Xeris” or ...

Xeris Pharmaceuticals (NASDAQ:XERS) is scheduled to announce Q4 earnings results on Thursday, March 10th, before market open. The consensus EPS Estimate is -$0.16 (compared to -$11 a year ago) and the consensus Revenue Estimate is $18.99M (+167.8% Y/Y). Over the last 1 year, XERS has bea...

AFCG, AG, AMTX, ATY, AUTL, BBW, BTAI, BZUN, CCLP, DCBO, DESP, DLTH, EMAN, ENG, ESTE, EVGN, EXK, FCEL, GNCA, GWRS, JD, KNOP, LAZY, LIZI, ML, NEON, OTCQX:QTRHF, SELB, SHIP, TEO, THRY, TXMD, UP, VITL, XERS For Seeking Alpha's full earnings season calendar, click here. For further details see: ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Company will release its fourth quarter and full year 2021 finan...

Xeris recently updated on full-year 2021 sales, reporting that it had hit the upper end of guidance for Gvoke and Keveyis. Recorlev was approved just before year-end 2021, and now Xeris gets to leverage its existing endocrinology sales force to start commercializing it. Currently ...

The following slide deck was published by Xeris Biopharma Holdings, Inc. in conjunction with this event. For further details see: Xeris Biopharma (XERS) Investor Presentation - Slideshow

Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and CEO of Xeris Biopharma, will participate in a ...